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1. Introduction
Hyperemesis gravidarum (HG), a pregnancy-related 
condition marked by extreme nausea and vomiting, occurs 
in 0.5%–2% of all pregnancies. This condition usually 
begins between the 4th and the 10th weeks of gestation 
and disappears spontaneously at the 20th week of gestation 
(1). Fluid, electrolyte and acid–base imbalance, nutritional 
deficiencies, and weight loss are the expected important 
side effects (1). For these reasons, hospitalization and 
intravenous hydration therapy or parenteral nutrition 
may be necessary. This period may lead to depression 
and decrease in the patient’s quality of life. The financial 
burden on the health system due to hospitalization and 
on the patient due to time lost from work is another 
significant problem (2). Furthermore, it is associated with 
adverse pregnancy outcomes such as low birth weight and 
preterm birth (2).
Although endocrinological, psychoneurotic, 
environmental, and genetic factors are considered as 
potential causes for HG, the extant literature on this 
issue does not offer a definitive answer pertaining to the 
potential cause (3).
Ghrelin, a gastric-derived peptide, is known as an 
appetite-stimulating hormone (4). It regulates food intake, 
energy metabolism, and growth hormone secretion 
both by central and peripheral action (5,6). The level of 
ghrelin increases before eating and decreases after a meal 
(7). Moreover, ghrelin influences sleep; controls gastric 
motility, acid secretion, pancreatic secretion, glucose 
and lipid metabolism, and cell proliferation; and exerts 
cardiovascular and antiinflammatory effects (8,9). It has 
recently been reported that ghrelin plays an important 
role in reproductive functions, such as the regulation 
of gonadal function, gonadotrophin secretion, embryo 
development, implantation, and prenatal growth (9–11). 
Maternal ghrelin concentration begins to increase in the 
first trimester, reaches the highest level at mid-pregnancy, 
and reduces to the lowest level in the third trimester (12).
The observed high ghrelin levels in the first trimester of 
pregnancy raises the question as to whether this hormone 
can serve as a distinctive marker for HG. To answer this 
question, we examined the relationship between HG and 
ghrelin levels in pregnant women. 
Aim: To investigate serum levels of ghrelin in pregnant women as a potential early marker for hyperemesis gravidarum (HG). 
Materials and methods: A cross-sectional study was carried out at Fatih University Hospital. Included in the study were 35 women 
with HG and 31 pregnant women without HG as a control group. The groups were compared in terms of age, gravidity, body mass index 
(BMI), and fasting serum thyroid-stimulating hormone (TSH) and ghrelin levels.
Results: Ghrelin levels of the patients with HG were found to be significantly lower than those in the control group (P = 0.03). No 
intergroup differences could be found in serum TSH or BMI values .
Conclusion: Ghrelin might serve as a reliable marker in the etiopathogenesis of HG.
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2. Materials and methods
This cross-sectional study was performed at the Medical 
School of Fatih University, Ankara, Turkey. Included in the 
study were 35 pregnant women with HG and 31 pregnant 
women in the first trimester without any symptoms whose 
age, prepregnancy weight, and gravidity matched those of 
the women in the study group, for a total of 66 cases.
HG was defined as severe nausea and vomiting, 
positive ketonuria (++++) in urine samples with no other 
detectable causes, and 2 or more hospitalizations during 
the present pregnancy because of electrolyte imbalance.
Any patient known to have hepatic and/or renal 
dysfunction, gastritis, or thyroid diseases was excluded 
from the study.
This study was approved by the Fatih University Ethics 
Committee and complied with the Helsinki Declaration, 
including current revisions and Good Clinical Practice 
guidelines. All the women signed written informed 
consent forms before the start of the study.
Both the study and the control groups were examined 
with respect to age, parity, and body mass index (BMI). The 
gestational age of the pregnancy in weeks was determined 
according to the last menstruation date and first trimester 
ultrasonographic measurements for both groups. BMI was 
calculated as weight in kilograms divided by the square of 
height in meters for all subjects.
To determine fasting serum ghrelin and thyroid-
stimulating hormone (TSH) levels, blood samples were 
collected in tubes containing EDTA-Na and aprotinin 
between 0830 and 1000 hours, centrifuged immediately at 
4 °C, and then frozen at −80 °C for a maximum of 3 months 
before processing. Plasma ghrelin levels were determined 
using enzyme linked immunosorbent assay (ELISA) 
methods (ELISA, Phoenix Pharmaceuticals, Belmont, 
CA, USA). TSH was determined by chemiluminometric 
assay using an ADVIA Centaur XP immunoassay system 
(Siemens Healthcare Diagnostics, Deerfield, IL, USA).
Statistical analyses were performed using SPSS 16.0 
for Windows (SPSS Inc., Chicago, IL, USA). Continuous 
variables were first inspected for normality of statistical 
distribution graphically and by Shapiro–Wilk test. Data 
were reported as mean ± standard deviation (SD) or 
median with interquartile ranges (IQRs), as appropriate. 
The nonparametric Mann–Whitney U test was used 
to analyze the significance of the differences between 
the control and HG groups. P ≤ 0.05 was used to define 
significance in all statistical comparisons.
3. Results
The study included 66 pregnant women between the 
6th and 10th gestational weeks. There were 35 pregnant 
women diagnosed with HG, who were classified as the 
study group, and the remaining 31 women constituted 
the control group. Characteristics of the patients are 
summarized in the Table. The 2 groups showed similarities 
in terms of age, gravidity, preconception body mass index, 
and gestational age, as shown in the Table. There were no 
differences in TSH levels between the groups. Ghrelin 
levels were statistically lower in the HG group (47.0 ± 22.9 
ng/mL) than in control subjects (62.4 ± 17.0 ng/mL) (P = 
0.026). The Figure shows the ghrelin levels for the groups.
Table. Characteristics of patients and levels of ghrelin between the groups.
HG (n = 35) Control (n = 31) P-value
Age (years) 29.4 ± 5.6 29.3 ± 4.6 0.87
Gravidity 2.0 (1.0) 2.0 (1.0) 0.77
P-BMI (kg/m2) 23.2 ± 3.2 23.5 ± 4.1 0.86
Gestational age (weeks) 8.2 ± 1.4 8.8 ± 1.5 0.89
Ghrelin (ng/mL) 47.0 ± 22.9 62.4 ± 17.0 0.03*
TSH (mIU/L) 1.1 ± 1.4 1.0 ± 0.9 0.45
Data are mean ± SD or median with IQR. *: Statistically significant.
Abbreviations: HG, hyperemesis gravidarum; P-BMI, preconception body mass index; TSH, thyroid stimulating 
hormone.
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Figure. Levels of ghrelin between the groups (ng/mL).
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4. Discussion 
Although some endocrine factors are often cited as 
the primary cause for HG, its exact cause still remains 
unknown. Several placental products, such as human 
chorionic gonadotropin (hCG), estradiol, and thyroid 
hormones, are considered to be related to this condition. 
HG has a higher incidence when the hCG levels peak, 
and in twin and molar pregnancies, which are associated 
with elevated hCG levels, HG is more common (13). 
Similarly, the symptoms of HG coincide with high 
progesterone levels in the first trimester of pregnancy. In 
addition, slower intestinal transit and gastric emptying 
time, distension of the upper gastrointestinal tract, trace 
element and vitamin deficiency, Helicobacter pylori 
infection, and environmental and genetic factors are 
considered as causes of HG (3). HG has been suggested 
to be related to the activity of pyridoxine and Wibowa et 
al. found significantly lower concentration levels of total 
plasma vitamin B6 in pregnant women with nausea and/or 
vomiting. They revealed that vitamin B6 supplementation 
significantly affected the clinical symptoms of nausea and 
vomiting (14). In a study by Chittumma et al. (15), 650 mg 
of ginger or 25 mg of vitamin B6 was given to women with 
hyperemesis 3 times per day for 4 days and Rhode’s score 
implemented to quantify patients’ nausea. Both ginger 
and vitamin B6 were effective for the treatment of nausea 
and vomiting in pregnancy. Moreover, ginger was more 
effective than vitamin B6. 
Because of inconsistent findings, a consensus about 
the cause and mechanism of HG has not yet been reached. 
Some studies looked over the other peptides that affect 
food intake and appetite, such as leptin. They examined the 
relationship between the severity of nausea and vomiting 
and the alterations in the levels of leptin and found higher 
serum leptin levels in pregnant women with HG than in 
women without nausea and vomiting (16,17). Although 
numerous research studies have been carried out to 
elucidate the relationship between maternal serum leptin 
levels and HG, this study is, to the best of our knowledge, 
the first to investigate the relationship between maternal 
serum ghrelin levels and HG. In the present study, maternal 
serum ghrelin levels were found to be significantly lower 
in the study group than in the control group. Ghrelin is 
an orexigenic hormone identified as an endogenous ligand 
of the growth hormone secretagogue receptor (ghrelin 
receptor) (6). It stimulates food intake (5) and triggers a 
positive energy balance through central and peripheral 
action (6,7). The level of ghrelin increases before eating 
and decreases after a meal (7), which means plasma 
ghrelin and oral intake correlate negatively. However, in 
the present study, plasma ghrelin levels and reduced oral 
intake correlated positively. This suggests that the lower 
ghrelin levels are not the result of, but are rather the cause 
of, reduced oral intake during HG. In the study by Shintani 
et al. (6), a single intracerebroventricular injection of 
ghrelin caused a significant and dose-related increase 
in cumulative food intake in rats. They demonstrated 
that ghrelin, a novel orexigenic peptide, activates the 
hypothalamic neuropeptide Y/Y1 receptor pathway and 
this effect results in antagonizing leptin action in the 
body. In another study, Yakabi et al. (18) demonstrated 
a significant increase in hypothalamic ghrelin levels in 
rats fasted for 24 h and a significant decrease in cisplatin-
treated rats during the early stage of anorexia, although 
their plasma ghrelin levels were comparable. On the other 
hand, Hiura et al. (19) found lower plasma ghrelin levels 
and feeding activity with cisplatin-based chemotherapy 
and reported that the extent of ghrelin reduction correlated 
well with adverse events, especially with neutropenia and 
anorexia. Furthermore, administration of intravenous 
ghrelin improved oral feeding and was effective against 
weight loss after total gastrectomy in cancer patients.
Ghrelin is mainly produced in the stomach, but it is 
also produced in the central nervous system, kidneys, 
heart, parathyroid glands, salivary glands, pituitary, small 
intestine, pancreas, hypothalamus, and placenta (20). It 
has been reported that both mRNAs for ghrelin and its 
functional receptor are present in the human placenta 
(primarily in cytotrophoblasts) during normal pregnancy, 
and ghrelin levels increase in the first trimester of 
pregnancy but not in the third trimester (12). This suggests 
a role for this hormone as an autocrine/paracrine factor 
for the growth and maintenance of the placenta during 
pregnancy. 
Ghrelin has an inhibitory effect on human myometrial 
contractility in vitro. Low levels of ghrelin in the third-
trimester myometrium are thought to prepare the 
uterus prior to labor (21). However, in term pregnancy, 
the placental ghrelin–ghrelin receptor system in the 
intrauterine growth restriction of rat models is speculated 
to continue to operate for the compensation of fetal 
development and fetoplacental circulation (22). It was 
proposed that chronic treatment of mothers with ghrelin 
during the last stage of pregnancy prompts fetal growth 
through stimulation of cell proliferation (23). Moreover, in 
small-for-gestational-age neonates, umbilical cord ghrelin 
plasma concentrations were higher than in appropriate- and 
large-for-gestational-age neonates (24). In another study, 
Aydin et al. (25) found higher maternal serum, arterial, and 
venous cord blood ghrelin levels in preeclamptic pregnant 
women than in healthy controls. They commented on this 
increase as a compensatory response to preeclampsia in an 
effort to contribute fetal growth, as ghrelin was detected 
to be involved in several growth-related processes. 
Physiological properties of ghrelin are thought to be a 
consequence of its relationship with human placental 
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growth hormone, which alters maternal metabolism 
during pregnancy by raising maternal insulin resistance, in 
order to increase nutrient availability for the fetoplacental 
unit (21). Ghrelin induces hyperglycemia and decreases 
plasma insulin concentrations, and ghrelin concentrations 
decrease with hyperglycemia and hyperinsulinism (25). 
Tham et al. (26) found markedly low acylated ghrelin 
levels during pregnancy, likely because of a decrease in 
the acylation process, and high desacyl ghrelin levels in 
gestational diabetes, possibly reflecting resistance to the 
inhibitory effect of insulin on ghrelin secretion. 
In the present study we found significantly lower 
maternal serum ghrelin levels in the HG group than in 
the control group. Recent studies have reported a negative 
correlation of serum ghrelin levels with food intake in 
normal conditions. However, in the present study, plasma 
ghrelin levels and reduced oral intake correlated positively. 
This suggests that the lower ghrelin levels are not the result 
of, but are rather the cause of, reduced oral intake during 
HG. However, whether the origin of the ghrelin is placental 
or it is secreted from the stomach, hypothalamus, or other 
tissues is presently unknown. If we had examined the 
source of ghrelin, we could have more easily interpreted 
whether the decrease in ghrelin level was due to a decreased 
production by the placenta or gastric mucosa, which was 
affected by H. pylori infection. Recently a metaanalysis 
concluded that circulating ghrelin is significantly lower 
in H. pylori-positive subjects (27). Another limitation is 
that we did not analyze ghrelin levels in the prepregnancy 
period, during the course of pregnancy longitudinally, 
after delivery, and in the cord blood. With these analyses, 
the effects of ghrelin on the fetus and the ways in which 
it affects other pregnancy complications could have 
concluded. Another limitation was that we did not analyze 
any other etiopathogenic factors that could have affected 
ghrelin levels. To have surveyed the level of leptin or to 
have determined the presence or absence of H. pylori 
infection could have enriched our interpretation. It would 
be understandable if there were a balance between leptin 
and ghrelin in order to maintain the normal physiology of 
pregnancy.
The proposed mechanism for ghrelin to cause HG may 
be a fluctuation of circulating ghrelin levels in relation to 
meal intake and its effects on appetite, causing nausea and 
vomiting to become more severe. Another hypothesis is 
that ghrelin may decrease progesterone levels, as suggested 
by Rak-Mardyła et al. (28). In the present study, the low 
ghrelin levels found for the HG group may be a trigger for 
nausea and vomiting, through elevated progesterone levels. 
Many pathogenic mechanisms and causes have been 
hypothesized and studied to identify the pathogenesis of 
HG. However, no consensus on its cause and mechanism 
has been reached. Until the etiology and pathogenesis 
of HG are known, treatment or patient care will remain 
empirical and therefore will be suboptimal. Our study 
contributes to this strand of literature by reporting a 
significant negative relationship between ghrelin levels 
and HG during pregnancy. Prospective studies with a 
larger sample size are needed to find out the possible role 
of these hormones in the pathogenesis, development, and 
management of HG.
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